SG11201901435UA - Monoclonal antibody against melk and utilization thereof - Google Patents
Monoclonal antibody against melk and utilization thereofInfo
- Publication number
- SG11201901435UA SG11201901435UA SG11201901435UA SG11201901435UA SG11201901435UA SG 11201901435U A SG11201901435U A SG 11201901435UA SG 11201901435U A SG11201901435U A SG 11201901435UA SG 11201901435U A SG11201901435U A SG 11201901435UA SG 11201901435U A SG11201901435U A SG 11201901435UA
- Authority
- SG
- Singapore
- Prior art keywords
- melk
- methods
- utilization
- monoclonal antibody
- antibody against
- Prior art date
Links
- 101150054634 melk gene Proteins 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 102100024299 Maternal embryonic leucine zipper kinase Human genes 0.000 abstract 3
- 101710154611 Maternal embryonic leucine zipper kinase Proteins 0.000 abstract 3
- DKZYXHCYPUVGAF-UHFFFAOYSA-N 1-[6-(3,5-dichloro-4-hydroxyphenyl)-4-[[4-[(dimethylamino)methyl]cyclohexyl]amino]-1,5-naphthyridin-3-yl]ethanone Chemical compound CN(C)CC1CCC(CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O DKZYXHCYPUVGAF-UHFFFAOYSA-N 0.000 abstract 2
- 229940124787 MELK inhibitor Drugs 0.000 abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Developmental Biology & Embryology (AREA)
Abstract
MONOCLONAL ANTIBODY AGAINST MELK AND UTILIZATION THEREOF The present invention relates to monoclonal antibodies against MELK. Furthermore, 5 the present invention provides methods for diagnosing MELK-associated diseases using the antibodies, methods for detecting the MELK protein, methods for determining the drug efficacy following treatment with a MELK inhibitor, methods of screening for subjects to whom a MELK inhibitor has a high therapeutic effect, and diagnostic reagents containing the antibodies. 10 [FIG. 1]
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016169085 | 2016-08-31 | ||
PCT/JP2017/030443 WO2018043311A1 (en) | 2016-08-31 | 2017-08-25 | Monoclonal antibody against melk and utilization thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201901435UA true SG11201901435UA (en) | 2019-03-28 |
Family
ID=61301839
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202100683RA SG10202100683RA (en) | 2016-08-31 | 2017-08-25 | Monoclonal antibody against melk and utilization thereof |
SG11201901435UA SG11201901435UA (en) | 2016-08-31 | 2017-08-25 | Monoclonal antibody against melk and utilization thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202100683RA SG10202100683RA (en) | 2016-08-31 | 2017-08-25 | Monoclonal antibody against melk and utilization thereof |
Country Status (14)
Country | Link |
---|---|
US (1) | US11066477B2 (en) |
EP (1) | EP3508576A4 (en) |
JP (1) | JP7094557B2 (en) |
KR (1) | KR102579047B1 (en) |
CN (1) | CN109890963B (en) |
AU (1) | AU2017318907B2 (en) |
BR (1) | BR112019003408A2 (en) |
CA (1) | CA3035160A1 (en) |
IL (1) | IL264826B2 (en) |
MX (1) | MX2019002269A (en) |
RU (1) | RU2756982C2 (en) |
SG (2) | SG10202100683RA (en) |
TW (1) | TWI780067B (en) |
WO (1) | WO2018043311A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022536247A (en) * | 2019-06-07 | 2022-08-15 | アディマブ・リミテッド・ライアビリティ・カンパニー | High affinity anti-CD3 antibodies and methods of making and using the same |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
DE69333807T2 (en) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | MARKERS FOR CANCER AND BIOSYNTHETIC BINDEPROTEIN THEREFOR |
US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
JP5087059B2 (en) | 2001-10-31 | 2012-11-28 | 杏林製薬株式会社 | Process for producing 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutanamide |
TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
US8067181B2 (en) | 2003-08-14 | 2011-11-29 | Exelixis, Inc. | MELKS as modifiers of the Rac pathway and methods of use |
WO2005073374A1 (en) | 2004-01-29 | 2005-08-11 | Dainippon Sumitomo Pharma Co., Ltd. | Novel tumor antigen protein and utilization of the same |
JP5028601B2 (en) | 2004-08-10 | 2012-09-19 | オンコセラピー・サイエンス株式会社 | Breast cancer-related genes and polypeptides |
US7998695B2 (en) | 2005-02-10 | 2011-08-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
US20090317392A1 (en) | 2005-07-27 | 2009-12-24 | Yusuke Nakamura | Method of diagnosing small cell lung cancer |
JP2009515527A (en) | 2005-11-10 | 2009-04-16 | エクセリクシス, インク. | KIFs as RHO pathway modifiers and methods of use |
WO2008023841A1 (en) | 2006-08-25 | 2008-02-28 | Oncotherapy Science, Inc. | Breast cancer-associated gene, melk, and its interactions with bcl-g |
WO2009131365A2 (en) * | 2008-04-21 | 2009-10-29 | 한국생명공학연구원 | Cst1, dcc1, ifitm1 or melk as markers for diagnosing stomach cancer |
TWI466680B (en) | 2008-08-01 | 2015-01-01 | Oncotherapy Science Inc | Melk epitope peptides and vaccines containing the same |
TWI485245B (en) | 2010-01-25 | 2015-05-21 | Oncotherapy Science Inc | Modified melk peptides and vaccines containing the same |
SG187633A1 (en) | 2010-07-30 | 2013-03-28 | Oncotherapy Science Inc | Quinoline derivatives and melk inhibitors containing the same |
EP2574929A1 (en) * | 2011-09-28 | 2013-04-03 | IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. | Marker in diagnosing prostate cancer (PC) |
BR112014014877B1 (en) | 2012-01-19 | 2020-09-08 | Oncotherapy Science, Inc. | 1,5-NAFTHYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME, ITS USE, PHARMACEUTICAL COMPOSITION, MELK INHIBITOR, MELK EXPRESSION AGENT, ANTITUMORAL AGENT AND THERAPEUTIC AND / OR PREVENTIVE AGENT FOR A SUPEREX PRESSURE DISEASE. , CONTAINING THE SAME |
RU2504785C1 (en) * | 2012-11-23 | 2014-01-20 | Общество с ограниченной ответственностью "Синтавр" | Diagnostic technique for breast cancer |
EP2943505B1 (en) * | 2013-01-11 | 2018-04-11 | Novartis AG | Melk regulation for the treatment of breast cancer |
EP3239295A4 (en) | 2014-12-12 | 2018-10-31 | Kyoto University | Antibody highly specifically recognizing turn structure at 22- and 23-positions in amyloid beta |
-
2017
- 2017-08-25 BR BR112019003408A patent/BR112019003408A2/en unknown
- 2017-08-25 JP JP2018537214A patent/JP7094557B2/en active Active
- 2017-08-25 AU AU2017318907A patent/AU2017318907B2/en active Active
- 2017-08-25 IL IL264826A patent/IL264826B2/en unknown
- 2017-08-25 CN CN201780067183.0A patent/CN109890963B/en active Active
- 2017-08-25 US US16/328,259 patent/US11066477B2/en active Active
- 2017-08-25 RU RU2019107355A patent/RU2756982C2/en active
- 2017-08-25 EP EP17846316.2A patent/EP3508576A4/en active Pending
- 2017-08-25 KR KR1020197009204A patent/KR102579047B1/en active IP Right Grant
- 2017-08-25 SG SG10202100683RA patent/SG10202100683RA/en unknown
- 2017-08-25 SG SG11201901435UA patent/SG11201901435UA/en unknown
- 2017-08-25 CA CA3035160A patent/CA3035160A1/en active Pending
- 2017-08-25 MX MX2019002269A patent/MX2019002269A/en unknown
- 2017-08-25 WO PCT/JP2017/030443 patent/WO2018043311A1/en unknown
- 2017-08-28 TW TW106129146A patent/TWI780067B/en active
Also Published As
Publication number | Publication date |
---|---|
EP3508576A4 (en) | 2020-04-22 |
MX2019002269A (en) | 2019-09-18 |
KR102579047B1 (en) | 2023-09-14 |
RU2019107355A (en) | 2020-10-01 |
EP3508576A1 (en) | 2019-07-10 |
BR112019003408A2 (en) | 2019-06-25 |
AU2017318907B2 (en) | 2023-07-06 |
AU2017318907A2 (en) | 2019-03-28 |
WO2018043311A1 (en) | 2018-03-08 |
JP7094557B2 (en) | 2022-07-04 |
TW201818972A (en) | 2018-06-01 |
IL264826A (en) | 2019-04-30 |
RU2019107355A3 (en) | 2020-11-02 |
TWI780067B (en) | 2022-10-11 |
SG10202100683RA (en) | 2021-03-30 |
CA3035160A1 (en) | 2018-03-08 |
CN109890963B (en) | 2023-10-03 |
KR20190043591A (en) | 2019-04-26 |
US20190185575A1 (en) | 2019-06-20 |
RU2756982C2 (en) | 2021-10-07 |
IL264826B1 (en) | 2024-02-01 |
IL264826B2 (en) | 2024-06-01 |
CN109890963A (en) | 2019-06-14 |
AU2017318907A1 (en) | 2019-03-21 |
JPWO2018043311A1 (en) | 2019-06-24 |
US11066477B2 (en) | 2021-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019501146A1 (en) | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging | |
CR20130621A (en) | ANTI-ANGPTL3 ANTIBODIES AND USES OF THE SAME | |
SG10201906750XA (en) | Assays for detecting the presence or amount of an anti-drug antibody | |
MY184154A (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
MX2018009011A (en) | Anti-ror1 antibodies and uses thereof. | |
WO2014144763A3 (en) | High affinity anti-gd2 antibodies | |
EA201691438A1 (en) | ANTIBODY WHICH IS CONNECTED WITH ERBB-2 AND ERBB-3 | |
ATE553778T1 (en) | ANTIBODIES SPECIFIC TO HUMAN HEPCIDIN | |
BR112019010595A2 (en) | antibody or antigen binding fragment thereof, combination of isolated nucleic acid molecules, pharmaceutical composition, kit, and method for selecting a compound. | |
MX2020000186A (en) | Assays for assessing neutralizing antibodies levels in subjects treated with a biological drug and uses thereof in personalized medicine. | |
EA202091810A1 (en) | ANTIBODIES TO B7-H4 AND METHODS OF THEIR APPLICATION | |
BR112022003956A2 (en) | anti-cd73 antibodies | |
PH12019501837A1 (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
MX2020008730A (en) | B7-h4 antibody dosing regimens. | |
WO2015013508A3 (en) | Methods for diagnosing and treating immune disease | |
MX2021006980A (en) | Anti-il-27 antibodies and uses thereof. | |
EA202091569A1 (en) | MONOCLONAL ANTIBODIES AND METHODS OF THEIR APPLICATION | |
ZA201804705B (en) | Monoclonal antibodies specific for the piii antigen of human adenovirus (adv), produced and secreted by cell hybridomas, useful for detection and diagnosis of adv infection | |
MX2018009499A (en) | Egfl6 specific monoclonal antibodies and methods of their use. | |
EP4300101A3 (en) | Antigenic peptides and uses thereof for diagnosing and treating autism | |
SG10201806729VA (en) | Novel assay to detect human periostin | |
SG11201901435UA (en) | Monoclonal antibody against melk and utilization thereof | |
BR112019006422A2 (en) | monoclonal antibody against fzd10 and use of it | |
RU2014113841A (en) | METHOD FOR EARLY DIAGNOSTICS OF ENDOGENOUS INTOXICATION | |
NZ751193A (en) | Protein biomarkers for diseases associated with the contact activation system |